Autologous stem-cell transplant plus rituximab for newly diagnosed mantle cell lymphoma: Up-date of a phase II trial

被引：0
|
作者：
Hicks, L
Mangel, J
Connors, J
Buckstein, R
Leitch, H
Imrie, K
Crump, M
Spaner, D
Pennell, N
Nagy, T
Boudreau, A
Berinstein, N
机构：
[1] Sunnybrook & Womens Coll Hosp, Toronto, ON, Canada
[2] London Hlth Sci Ctr, London, ON, Canada
[3] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada
[4] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
来源：
ANNALS OF ONCOLOGY | 2005年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
454
引用
收藏
页码：170 / 170
页数：1
相关论文
共 50 条
  • [31] Autologous Stem Cell Transplant: Still the Standard for Fit Patients With Mantle Cell Lymphoma
    Staton, Ashley D.
    Langston, Amelia A.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S96 - S99
  • [32] Immunologic recovery following autologous stem-cell transplantation with pre- and posttransplantation rituximab for low-grade or mantle cell lymphoma
    Kasamon, Y. L.
    Jones, R. J.
    Brodsky, R. A.
    Fuchs, E. J.
    Matsui, W.
    Luznik, L.
    Powell, J. D.
    Blackford, A. L.
    Goodrich, A.
    Gocke, C. D.
    Abrams, R. A.
    Ambinder, R. F.
    Flinn, I. W.
    ANNALS OF ONCOLOGY, 2010, 21 (06) : 1203 - 1210
  • [33] Ibrutinib, Venetoclax Plus Obinutuzumab in Newly Diagnosed Mantle Cell Lymphoma Patients
    Le Gouill, Steven
    Morschhauser, Franck
    Bouabdallah, Kamal
    Cartron, Guillaume
    Casasnovas, Olivier
    Gastinne, Thomas
    Chevallier, Patrice
    Rossi, Cedric
    Tchernonog, Emmanuelle
    McCulloch, Rory
    Herbaux, Charles
    Chiron, David
    Callanan, Mary
    Rule, Simon
    BLOOD, 2019, 134
  • [34] A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma
    Dreyling, Martin
    Tam, Constantine S.
    Wang, Michael
    Smith, Stephen D.
    Ladetto, Marco
    Huang, Huiqiang
    Novotny, William
    Co, Melannie
    Romano, Alfredo
    Holmgren, Eric
    Huang, Jane
    Le Gouill, Steven
    FUTURE ONCOLOGY, 2021, 17 (03) : 255 - 262
  • [35] Phase II study of rituximab and cladribine (2-CDA) in newly diagnosed mantle cell lymphoma (MCL) (N0189).
    Inwards, David James
    Hillman, David. W.
    Fishkin, Paul A.
    White, William L.
    Morton, Roscoe F.
    Dakhil, Shaker R.
    Nikcevich, Daniel A.
    Wender, Donald B.
    Fitch, Tom R.
    Kurtin, Paul J.
    BLOOD, 2006, 108 (11) : 777A - 777A
  • [36] A randomized phase II trial of maintenance versus consolidation bortezomib therapy following aggressive chemoimmunotherapy and autologous stem cell transplant for previously untreated mantle cell lymphoma
    Kaplan, L. D.
    Jung, S.
    Johnson, J. L.
    Linker, C. A.
    Byrd, J. C.
    Stock, W.
    Hsi, E. D.
    Cheson, B. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [37] R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma
    Omuro, Antonio
    Correa, Denise D.
    DeAngelis, Lisa M.
    Moskowitz, Craig H.
    Matasar, Matthew J.
    Kaley, Thomas J.
    Gavrilovic, Igor T.
    Nolan, Craig
    Pentsova, Elena
    Grommes, Christian C.
    Panageas, Katherine S.
    Baser, Raymond E.
    Faivre, Geraldine
    Abrey, Lauren E.
    Sauter, Craig S.
    BLOOD, 2015, 125 (09) : 1403 - 1410
  • [38] Phase II trial of bortezomib in mantle cell lymphoma
    Belch, A
    Kouroukis, CT
    Crump, M
    Sehn, L
    Gascoyne, R
    Klasa, R
    Powers, J
    Eisenhauer, E
    BLOOD, 2004, 104 (11) : 175A - 176A
  • [39] Results of a Phase II trial of gemcitabine, mitoxantrone, and rituximab in relapsed or refractory mantle cell lymphoma
    Garbo, Lawrence E.
    Flynn, Patrick J.
    MacRae, Margaret A.
    Rauch, Mary A.
    Wang, Yunfei
    Kolibaba, Kathryn S.
    INVESTIGATIONAL NEW DRUGS, 2009, 27 (05) : 476 - 481
  • [40] Results of a Phase II trial of gemcitabine, mitoxantrone, and rituximab in relapsed or refractory mantle cell lymphoma
    Lawrence E. Garbo
    Patrick J. Flynn
    Margaret A. MacRae
    Mary A. Rauch
    Yunfei Wang
    Kathryn S. Kolibaba
    Investigational New Drugs, 2009, 27 : 476 - 481
12345